NR3C1 and diffuse large B-cell lymphoma: Taken together, our discovery of Nr3c1 as a major DLBCL CIS and its strong association with therapy response/resistance establishes NR3C1 as a bona fide tumor suppressor and predictive marker in human DLBCL.